Literature DB >> 27038659

Gabapentin concentrations and postmortem distribution.

Catherine E Hamm1, Ray D Gary2, Iain M McIntyre3.   

Abstract

Gabapentin is a widely prescribed medication used primarily for the treatment of epilepsy and neuropathic pain. Gabapentin has a favorable adverse effect profile in therapeutic dosing with the most common reported effects being dizziness, fatigue, drowsiness, weight gain, and peripheral edema. Even with intentional self-poisonings, serious effects are generally rare. In this report, gabapentin analyses were performed on 30 postmortem cases that had peripheral blood, central blood and liver tissue. Overall the central to peripheral blood (C/P) ratio mean was 0.90±0.24 (mean±standard deviation), and a median of 0.97. The liver to peripheral blood (L/P) ratio mean was 0.68±0.26L/kg (mean±standard deviation), and a median of 0.65L/kg. An additional case, where both antemortem blood and postmortem peripheral blood specimens were available, revealed the same gabapentin concentration in both specimens. Taken together, the data presented suggests that gabapentin is unlikely to show postmortem redistribution.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Blood; Drug distribution; Gabapentin; Liver; Postmortem; Redistribution

Mesh:

Substances:

Year:  2016        PMID: 27038659     DOI: 10.1016/j.forsciint.2016.03.028

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  2 in total

1.  Fatalities associated with gabapentinoids in England (2004-2020).

Authors:  Nicola J Kalk; Ching-Ting Chiu; Rasa Sadoughi; Heli Baho; Bryn D Williams; David Taylor; Caroline S Copeland
Journal:  Br J Clin Pharmacol       Date:  2022-04-25       Impact factor: 3.716

2.  Analytical data supporting the "theoretical" postmortem redistribution factor (Ft ): a new model to evaluate postmortem redistribution.

Authors:  Iain M McIntyre
Journal:  Forensic Sci Res       Date:  2016-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.